Research progress of indoleamine 2,3-dioxygenase 1 in gastric cancer

Abstract

Gastric cancer is the fifth most common malignant tumor and fourth leading cause of cancerrelated deaths worldwide. Gastric cancer has obvious heterogeneity and complex tumor microenvironment. Although immune checkpoint inhibitors have shown certain anti-tumor efficacy in advanced gastric cancer, the beneficiaries are still a few. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key metabolic enzyme which catalyzes the degradation of tryptophan along the kynurenine pathway and plays an important role in tumor immune escape. At present, many studies have shown that IDO1 plays an important role in the development of gastric cancer, Helicobacter pylori infection and EB virus infection. Therefore, targeting IDO1 is expected to become a new strategy for immunotherapy of gastric cancer. This paper reviews the mechanism of IDO1，the research progress of IDO1 in gastric cancer and related diseases and the application prospect of IDO1 inhibitors in gastric cancer.

Keywords

• indoleamine 2，3-dioxygenase 1
• gastric cancer
• tumor microenvironment
• immunotherapy